Literature DB >> 30080235

Intramuscular botulinum toxin prior to comprehensive rehabilitation has no added value for improving motor impairments, gait kinematics and goal attainment in walking children with spastic cerebral palsy.

Fabienne Schasfoort1, Robert Pangalila, Emiel M Sneekes, Coriene Catsman, Jules Becher, Herwin Horemans, Henk J Stam, Annet J Dallmeijer, Johannes B J Bussmann.   

Abstract

OBJECTIVE: Botulinum toxin (BoNT-A) is widely used in combined treatment for spastic cerebral palsy, but its added value preceding comprehensive rehabilitation for motor impairments, gait, and goal attainment has not been studied.
DESIGN: A comparative multi-centre trial, in which two groups underwent comprehensive rehabilitation (i.e. high-intensive functional physiotherapy, and indicated casting/orthoses). One group received intramuscular BoNT-A prior to rehabilitation, and the other group did not receive BoNT-A. SUBJECTS/PATIENTS: Children with spastic cerebral palsy, Gross Motor Function Classification System (GMFCS) levels I-III, age range 4-12 years, indicated for BoNT-A treatment regarding mobility problems.
METHODS: Sixty-five children participated (37 boys), mean age 7.3 years (standard deviation (SD) 2.3, range 4-12 years), equally distributed across GMFCS levels. Forty-one children received BoNT-A+ comprehensive rehabilitation and 24 received comprehensive rehabilitation only. Functional leg muscle strength, passive range of motion, angle of catch, cerebral palsy-related pain, walking speed, kinematic gait parameters, goal attainment, and proxy-reported general functioning were assessed at baseline, primary end-point (12 weeks) and 24-week follow-up. Statistical analyses were performed with linear mixed models.
RESULTS: At the primary end-point there were no statistically significant differences in treatment effects between the groups, except for the angle-of-catch of the rectus femoris, which was in favour of comprehensive rehabilitation without BoNT-A (12° difference, 95% confidence interval (95% CI) 2:23, p = 0.025). Results at follow-up were similar.
CONCLUSION: At the group level, treating with BoNT-A prior to comprehensive rehabilitation did not add to the clinical effectiveness of rehabilitation. Thus, BoNT-A prescription and use should be critically reconsidered in this cerebral palsy age- and GMFCS-subgroup.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30080235     DOI: 10.2340/16501977-2369

Source DB:  PubMed          Journal:  J Rehabil Med        ISSN: 1650-1977            Impact factor:   2.912


  5 in total

1.  How does treadmill training contribute to botulinum toxin application plus routine physical therapy in ambulatory children with spastic bilateral cerebral palsy? A randomized controlled trial.

Authors:  Kübra Seyhan Bıyık; Mintaze Kerem Günel; Ece Ünlü Akyüz
Journal:  Ir J Med Sci       Date:  2022-02-27       Impact factor: 1.568

Review 2.  Nonsurgical Treatment Options for Muscle Contractures in Individuals With Neurologic Disorders: A Systematic Review With Meta-Analysis.

Authors:  Christian Svane; Jens Bo Nielsen; Jakob Lorentzen
Journal:  Arch Rehabil Res Clin Transl       Date:  2021-01-13

Review 3.  Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy.

Authors:  Francesco C Blumetti; João Carlos Belloti; Marcel Js Tamaoki; José A Pinto
Journal:  Cochrane Database Syst Rev       Date:  2019-10-08

4.  Botulinum Toxin A Injection in Treatment of Upper Limb Spasticity in Children with Cerebral Palsy: A Systematic Review of Randomized Controlled Trials.

Authors:  Sara M Farag; Manal O Mohammed; Tamer A El-Sobky; Nadia A ElKadery; Abeer K ElZohiery
Journal:  JBJS Rev       Date:  2020-03

5.  Relationship between changes in motor capacity and objectively measured motor performance in ambulatory children with spastic cerebral palsy.

Authors:  Elisabeth Halma; Johannes Bernardus Josephus Bussmann; Hendrika Johanna Gerarda van den Berg-Emons; Emanuel Maria Sneekes; Robert Pangalila; Fabienne Carmen Schasfoort
Journal:  Child Care Health Dev       Date:  2019-12-03       Impact factor: 2.508

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.